Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION (Details)

STOCK-BASED COMPENSATION (Details) - USD ($)	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ 165,016	$ 146,559	$ 428,561	$ 682,775
Employee and Director Stock Option Grants [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	168,068	162,141	426,157	681,660
Employee and Director Stock Option Grants [Member] \| Research and Development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	25,749	31,441	109,402	142,142
Employee and Director Stock Option Grants [Member] \| General and Administrative [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	142,319	130,700	316,755	491,665
Employee and Director Stock Option Grants [Member] \| Restructuring Costs [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	0	0	0	47,853
Non Employee Consultant Stock Option Grants [Member] \| Research and Development [Member]
Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Line Items]
Total stock-based compensation	$ (3,052)	$ (15,582)	$ 2,404	$ 1,115